Gap junction remodelling in human heart failure is associated with increased interaction of connexin43 with ZO-1
Author(s)
Bruce, AF
Rothery, S
Dupont, E
Severs, NJ
Type
Journal Article
Abstract
Aims
Remodelling of gap junctions, involving reduction of total gap junction quantity and down-regulation of connexin43 (Cx43), contributes to the arrhythmic substrate in congestive heart failure. However, little is known of the underlying mechanisms. Recent studies from in vitro systems suggest that the connexin-interacting protein zonula occludens-1 (ZO-1) is a potential mediator of gap junction remodelling. We therefore examined the hypothesis that ZO-1 contributes to reduced expression of Cx43 gap junctions in congestive heart failure.
Methods and results
Left ventricular myocardium from healthy control human hearts (n = 5) was compared with that of explanted hearts from transplant patients with end-stage congestive heart failure due to idiopathic dilated cardiomyopathy (DCM; n = 5) or ischaemic cardiomyopathy (ICM; n = 5). Immunoconfocal and immunoelectron microscopy showed that ZO-1 is specifically localized to the intercalated disc of cardiomyocytes in control and failing ventricles. ZO-1 protein levels were significantly increased in both DCM and ICM (P = 0.0025), showing a significant, negative correlation to Cx43 levels (P = 0.0029). There was, however, no significant alteration of ZO-1 mRNA (P = 0.537). Double immunolabelling demonstrated that a proportion of ZO-1 label is co-localized with Cx43, and that co-localization of Cx43 with ZO-1 is significantly increased in the failing ventricle (P = 0.003). Interaction between the two proteins was confirmed by co-immunoprecipitation. The proportion of Cx43 that co-immunoprecipitates with ZO-1 was significantly increased in the failing heart.
Conclusion
Our findings suggest that ZO-1, by interacting with Cx43, plays a role in the down-regulation and decreased size of Cx43 gap junctions in congestive heart failure.
Remodelling of gap junctions, involving reduction of total gap junction quantity and down-regulation of connexin43 (Cx43), contributes to the arrhythmic substrate in congestive heart failure. However, little is known of the underlying mechanisms. Recent studies from in vitro systems suggest that the connexin-interacting protein zonula occludens-1 (ZO-1) is a potential mediator of gap junction remodelling. We therefore examined the hypothesis that ZO-1 contributes to reduced expression of Cx43 gap junctions in congestive heart failure.
Methods and results
Left ventricular myocardium from healthy control human hearts (n = 5) was compared with that of explanted hearts from transplant patients with end-stage congestive heart failure due to idiopathic dilated cardiomyopathy (DCM; n = 5) or ischaemic cardiomyopathy (ICM; n = 5). Immunoconfocal and immunoelectron microscopy showed that ZO-1 is specifically localized to the intercalated disc of cardiomyocytes in control and failing ventricles. ZO-1 protein levels were significantly increased in both DCM and ICM (P = 0.0025), showing a significant, negative correlation to Cx43 levels (P = 0.0029). There was, however, no significant alteration of ZO-1 mRNA (P = 0.537). Double immunolabelling demonstrated that a proportion of ZO-1 label is co-localized with Cx43, and that co-localization of Cx43 with ZO-1 is significantly increased in the failing ventricle (P = 0.003). Interaction between the two proteins was confirmed by co-immunoprecipitation. The proportion of Cx43 that co-immunoprecipitates with ZO-1 was significantly increased in the failing heart.
Conclusion
Our findings suggest that ZO-1, by interacting with Cx43, plays a role in the down-regulation and decreased size of Cx43 gap junctions in congestive heart failure.
Date Issued
2008-03-01
Date Acceptance
2007-11-19
Citation
Cardiovascular Research, 2008, 77 (4), pp.757-765
ISSN
1755-3245
Publisher
Oxford University Press (OUP)
Start Page
757
End Page
765
Journal / Book Title
Cardiovascular Research
Volume
77
Issue
4
Copyright Statement
For permissions please email: journals.permissions@oxfordjournals.org.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display
the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the
Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if
an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated.
For commercial re-use, please contact journals.permissions@oxfordjournals.org.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display
the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the
Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if
an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated.
For commercial re-use, please contact journals.permissions@oxfordjournals.org.
Subjects
Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
CARDIAC & CARDIOVASCULAR SYSTEMS
gap junction remodelling
connexin43
ZO-1
conjestive heart failure
FAILING HUMAN HEART
CONDUCTION DEFECTS
CARDIAC MYOCYTES
TIGHT JUNCTION
EXPRESSION
PROTEIN
DISEASE
DOMAIN
LEADS
SIZE
Publication Status
Published